A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy.

Early urinary continence recovery Posterior rhabdosphincter reconstruction Robot-assisted radical prostatectomy

Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
08 2022
Historique:
received: 17 01 2021
revised: 05 02 2021
accepted: 16 02 2021
pubmed: 4 3 2021
medline: 4 8 2022
entrez: 3 3 2021
Statut: ppublish

Résumé

Posterior rhabdosphincter reconstruction (PRR) has been proposed to improve early urinary continence (UC) recovery after radical prostatectomy (RP). In order to generate level 1b evidence, we designed a double-blind randomised controlled trial powered to detect a 20% increase in early UC recovery after robot-assisted RP (RARP). A group of 153 patients with cT1c-3a N0M0 prostate cancer were randomised (73 to control arm and 80 to PRR arm) and 152 completed 12-mo follow-up. For UC defined as no pad use, the recovery hazard ratio at 1-mo follow-up was 2.312 (95% confidence interval [CI] 1.081-4.937; p =  0.030). UC recovery was observed in 33.8% of patients in the PRR arm and 18.1% of patients in the control arm (p =  0.022). At 3-mo follow-up the corresponding rates were 58.8% and 43.1% (p =  0.038). The median time to UC recovery was 106 d (95% CI 73-139) in the control arm and 64 d (95% CI 39-89) in PRR arm (p =  0.897). No differences in pathological outcomes or early and late surgical complications were observed between the arms. We conclude that PRR is safe and increases early UC recovery after RARP. PATIENT SUMMARY: We investigated reconstruction of a muscular ring that controls the flow of urine, called the rhabdosphincter, after removal of the prostate in robot-assisted surgery. The procedure is safe and increases early recovery of urinary continence. This trial is registered at ClinicalTrials.gov as NCT03302169.

Identifiants

pubmed: 33653674
pii: S2588-9311(21)00039-0
doi: 10.1016/j.euo.2021.02.005
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03302169']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

460-463

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Aina Salazar (A)

Department of Urology and Renal Transplantation, Vall d'Hebron Hospital, Barcelona, Spain.

Lucas Regis (L)

Department of Urology and Renal Transplantation, Vall d'Hebron Hospital, Barcelona, Spain; Prostate Cancer Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Jacques Planas (J)

Department of Urology and Renal Transplantation, Vall d'Hebron Hospital, Barcelona, Spain; Prostate Cancer Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Anna Celma (A)

Department of Urology and Renal Transplantation, Vall d'Hebron Hospital, Barcelona, Spain; Prostate Cancer Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Anna Santamaria (A)

Prostate Cancer Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.

Enrique Trilla (E)

Department of Urology and Renal Transplantation, Vall d'Hebron Hospital, Barcelona, Spain; Surgery Department, Universitat Autònoma of Barcelona, Barcelona, Spain.

Juan Morote (J)

Department of Urology and Renal Transplantation, Vall d'Hebron Hospital, Barcelona, Spain; Prostate Cancer Research Group, Vall d'Hebron Research Institute, Barcelona, Spain; Surgery Department, Universitat Autònoma of Barcelona, Barcelona, Spain. Electronic address: jmorote@vhebron.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH